SLC5A2 and brain cancer: For brain cancer, the mediation proportions of SGLT2 inhibition through medium-high-density lipoprotein triglycerides, high-density lipoprotein triglycerides, and very-low-density lipoprotein triglycerides were 2.648%, 2.131%, and 2.095%, respectively.